The BRIM-3 clinical trial substantiated that vemurafenib markedly enhanced OS and progression-free survival (PFS) in patients with untreated, metastatic melanoma harboring the BRAF V600E mutation, as compared to the use of dacarbazine (8). This evidence concerns the gene BRAF and metastatic melanoma.